The company, which manufactures and distributes mainly branded generic pharmaceuticals but has also made a move into innovative drugs, received a good response to its initial public offering, allowing it to fix the price at the top of the $12.50 to $14.50 range.
This resulted in a total deal size of $226.6 million, which ranks Simcere as the largest Chinese pharmaceutical sector IPO û in any market. Goldman Sachs was sole bookrunner for the offering, which also saw a number of...
¬ Haymarket Media Limited. All rights reserved.
